Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 14/20 | 0.72 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delprostenate SCHEMBL571387 | 0.88 | PTGFR (0.71) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL25329574 | 0.87 | PTGFR (0.86) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL16037398 | 0.87 | PTGFR (0.86) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL16037841 | 0.87 | PTGFR (0.86) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL13260245 | 0.87 | PTGFR (0.86) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL16037840 | 0.87 | PTGFR (0.86) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL16037395 | 0.87 | PTGFR (0.86) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL18558637 | 0.87 | PTGFR (0.86) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL16037401 | 0.87 | PTGFR (0.86) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL16037838 | 0.87 | PTGFR (0.86) | PTGFRPTGER3ABCC4ABCB11TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | claimed |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | claimed |
| US-8067414-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX S.A. (FR) | 2011-11-29 | — | — | US | claimed |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2010-09-23 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-2007705-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007126609-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-11-08 | — | — | WO | claimed |
| JP-2001515864-A | — | — | 2001-09-25 | — | — | JP | claimed |
| US-6156799-A | Method of increasing bone volume using non-naturally-occurring FP selective agonists | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-05 | — | — | US | claimed |
| EP-1045694-A1 | METHOD OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2000-10-25 | — | — | EP | claimed |
| CN-1269721-A | Methods of increasing bone volume with non-naturally-occurring FP selective agonists | PROCTER & GAMBLE (US) | 2000-10-11 | — | — | CN | claimed |
| CN-1269720-A | Method of increasing bone volume | PROCTER & GAMBLE (US) | 2000-10-11 | — | — | CN | claimed |
| EP-1035853-A1 | USE OF F PROSTANOID RECEPTOR AGONISTS FOR TREATING A BONE DISORDER | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-20 | — | — | EP | claimed |
| WO-2000051585-A2 | USE OF A NON-NATURALLY-OCCURRING EP1 SELECTIVE AGONIST FOR INCREASING BONE VOLUME | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | claimed |
| WO-2000051617-A1 | METHODS OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS AND ANTIRESORPTIVE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | claimed |
| WO-1999012551-A1 | METHOD OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-18 | — | — | WO | claimed |
| WO-1999012550-A1 | METHOD OF INCREASING BONE VOLUME | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, NOS1 | PTGFR 42/4885PTGER3 22/4885ABCC4 4339/4885 |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, PTGS1 | PTGFR 30/4885PTGER3 22/4885ABCC4 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.